<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYTHROMYCIN ETHYLSUCCINATE - erythromycin ethylsuccinate tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the 
effectiveness of erythromycin ethylsuccinate tablets and other antibacterial 
drugs, erythromycin ethylsuccinate tablets should be used only to treat or 
prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by 
bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccharopolyspora erythraea</span> (formerly <span class="Italics">Streptomyces erythraeus</span>) and belongs to the macrolide group 
of antibiotics. It is basic and readily forms salts with acids. The base, the 
stearate salt, and the esters are poorly soluble in water. Erythromycin 
ethylsuccinate is an ester of erythromycin suitable for oral administration. 
Erythromycin ethylsuccinate is known chemically as erythromycin 
2'-(ethylsuccinate).</p>
<p>Erythromycin ethylsuccinate tablets for oral administration are intended 
primarily for adults or older children. Each tablet contains erythromycin 
ethylsuccinate equivalent to 400 mg of erythromycin activity. The molecular 
formula is C<span class="Sub">43</span>H<span class="Sub">75</span>NO<span class="Sub">16</span> and the molecular weight is 862.06. The structural formula 
is:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d8c343b-30d9-4cdb-8f55-2a20983a71c1&amp;name=chemical%20structure.jpg"></p>
<a href="http://"></a>Inactive Ingredients<p>Confectioner's sugar (contains corn starch), corn starch, 
FD&amp;C Red No. 40, magnesium stearate, polacrilin potassium and sodium 
citrate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orally administered erythromycin ethylsuccinate tablets are 
readily and reliably absorbed under both fasting and nonfasting conditions.</p>
<p>Erythromycin diffuses readily into most body fluids. Only low concentrations 
are normally achieved in the spinal fluid, but passage of the drug across the 
blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. In the presence of normal hepatic 
function, erythromycin is concentrated in the liver and excreted in the bile; 
the effect of hepatic dysfunction on excretion of erythromycin by the liver into 
the bile is not known. Less than 5 percent of the orally administered dose of 
erythromycin is excreted in active form in the urine.</p>
<p>Erythromycin crosses the placental barrier, but fetal plasma levels are low. 
The drug is excreted in human milk.</p>
<a href="http://"></a>Microbiology<p>Erythromycin acts by inhibition of protein synthesis by binding 
50 <span class="Italics">S</span> ribosomal subunits of susceptible organisms. It 
does not affect nucleic acid synthesis. Antagonism has been demonstrated <span class="Italics">in vitro</span> between erythromycin and clindamycin, lincomycin, 
and chloramphenicol.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae </span>are 
resistant to erythromycin alone but are susceptible to erythromycin and 
sulfonamides used concomitantly.</p>
<p>Staphylococci resistant to erythromycin may emerge during a course of 
therapy.</p>
<p>Erythromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the 
following microorganisms, both <span class="Italics">in vitro </span>and in 
clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND 
USAGE</span> section.</p>
<a href="http://"></a><a href="http://"></a>Gram-positive organisms<p><span class="Italics">Corynebacterium diphtheriae</span></p>
<p><span class="Italics">Corynebacterium minutissimum</span></p>
<p><span class="Italics">Listeria monocytogenes</span></p>
<p><span class="Italics">Staphylococcus aureus</span> (resistant organisms may 
emerge during treatment)</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<a href="http://"></a><a href="http://"></a>Gram-negative organisms<p><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></p>
<p><span class="Italics">Legionella pneumophila</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<a href="http://"></a><a href="http://"></a>Other microorganisms<p><span class="Italics">Chlamydia trachomatis</span></p>
<p><span class="Italics">Entamoeba histolytica</span></p>
<p><span class="Italics">Mycoplasma pneumoniae</span></p>
<p><span class="Italics">Treponema pallidum</span></p>
<p><span class="Italics">Ureaplasma urealyticum</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold"><span class="Underline">but their clinical significance is 
unknown</span></span>.</p>
<p>Erythromycin exhibits <span class="Italics">in vitro </span>minimal inhibitory 
concentrations (MIC's) of 0.5 mcg/mL or less against most (≥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the 
following microorganisms; however, the safety and effectiveness of erythromycin 
in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been 
established in adequate and well-controlled clinical trials.</p>
<a href="http://"></a><a href="http://"></a>Gram-positive organisms<p>Viridans group streptococci</p>
<a href="http://"></a><a href="http://"></a>Gram-negative organisms<p><span class="Italics">Moraxella catarrhalis</span></p>
<a href="http://"></a><a href="http://"></a>Susceptibility Tests<a href="http://"></a><a href="http://"></a>Dilution Techniques<p>Quantitative methods are used to determine antimicrobial minimum 
inhibitory concentrations (MIC's). These MIC's provide estimates of the 
susceptibility of bacteria to antimicrobial compounds. The MIC's should be 
determined using a standardized procedure. Standardized procedures are based on 
a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with 
standardized inoculum concentrations and standardized concentrations of 
erythromycin powder. The MIC values should be interpreted according to the 
following criteria:</p>
<a href="http://"></a><a name="if2864161-7ec3-41fb-8b5a-8b17a4082c47"></a><table width="100%">
<col width="48%">
<col width="50%">
<thead><tr class="First Last">
<td><span class="Bold">MIC (mcg/mL)</span></td>
<td><span class="Bold">Interpretation </span></td>
</tr></thead>
<tbody>
<tr class="First">
<td>≤ 0.5</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>1-4</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td>≥ 8</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be 
inhibited if the antimicrobial compound in the blood reaches the concentrations 
usually achievable. A report of "Intermediate" indicates that the result should 
be considered equivocal, and, if the microorganism is not fully susceptible to 
alternative, clinically feasible drugs, the test should be repeated. This 
category implies possible clinical applicability in body sites where the drug is 
physiologically concentrated or in situations where high dosage of drug can be 
used. This category also provides a buffer zone which prevents small 
uncontrolled technical factors from causing major discrepancies in 
interpretation. A report of "Resistant" indicates that the pathogen is not 
likely to be inhibited if the antimicrobial compound in the blood reaches the 
concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory 
control microorganisms to control the technical aspects of the laboratory 
procedures. Standard erythromycin powder should provide the following MIC 
values:</p>
<a href="http://"></a><a name="id5103594-1d5d-448a-8e9a-dcb2bc752357"></a><table width="100%">
<col width="48%">
<col width="50%">
<thead><tr class="First Last">
<td><span class="Bold">Microorganism</span></td>
<td><span class="Bold">MIC (mcg/mL) </span></td>
</tr></thead>
<tbody>
<tr class="First">
<td>
<span class="Italics">S. aureus</span> ATCC 29213</td>
<td>0.12-0.5</td>
</tr>
<tr class="Last">
<td>
<span class="Italics">E. faecalis</span> ATCC 29212</td>
<td>1-4</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a>Diffusion Techniques<p>Quantitative methods that require measurement of zone diameters 
also provide reproducible estimates of the susceptibility of bacteria to 
antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> 
requires the use of standardized inoculum concentrations. This procedure uses 
paper disks impregnated with 15-mcg erythromycin to test the susceptibility of 
microorganisms to erythromycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk 
susceptibility test with a 15-mcg erythromycin disk should be interpreted 
according to the following criteria:</p>
<a href="http://"></a><a name="ife5c77de-4698-4b04-88ec-37a6144e7734"></a><table width="100%">
<col width="49%">
<col width="49%">
<thead><tr class="First Last">
<td><span class="Bold">Zone Diameter (mm)</span></td>
<td><span class="Bold">Interpretation </span></td>
</tr></thead>
<tbody>
<tr class="First">
<td>≥ 23</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>14-22</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td>≤ 13</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution 
techniques. Interpretation involves correlation of the diameter obtained in the 
disk test with the MIC for erythromycin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use 
of laboratory control microorganisms that are used to control the technical 
aspects of the laboratory procedures. For the diffusion technique, the 15-mcg 
erythromycin disk should provide the following zone diameters in these 
laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a href="http://"></a><a name="i58935e2b-5f94-4e2c-8998-cd7a15e73840"></a><table width="100%">
<col width="48%">
<col width="50%">
<thead><tr class="First Last">
<td><span class="Bold">Microorganism</span></td>
<td><span class="Bold">Zone Diameter (mm)</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td>
<span class="Italics">S. aureus</span> ATCC 25923</td>
<td>22-30</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain 
the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial 
drugs, erythromycin ethylsuccinate tablets should be used only to treat or 
prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by 
susceptible bacteria. When culture and susceptibility information are available, 
they should be considered in selecting or modifying antibacterial therapy. In 
the absence of such data, local epidemiology and susceptibility patterns may 
contribute to the empiric selection of therapy.</p>
<p>Erythromycin ethylsuccinate tablets are indicated in the treatment of 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the 
diseases listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> of mild to moderate degree caused by <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Streptococcus 
pneumoniae </span>, or <span class="Italics">Haemophilus influenzae</span> (when 
used concomitantly with adequate doses of sulfonamides, since many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of 
<span class="Italics">H. influenzae</span> are not susceptible to the erythromycin 
concentrations ordinarily achieved). (See appropriate sulfonamide labeling for 
prescribing information.)</p>
<p>Lower-<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span> of mild to moderate severity caused by 
<span class="Italics">Streptococcus pneumoniae</span> or <span class="Italics">Streptococcus pyogenes </span>.</p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> caused by <span class="Italics">Listeria monocytogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> (whooping <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) caused by <span class="Italics">Bordetella 
<span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span>. Erythromycin is effective in eliminating the organism from the 
nasopharynx of infected individuals rendering them noninfectious. Some clinical 
studies suggest that erythromycin may be helpful in the prophylaxis of <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> 
in exposed susceptible individuals.</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to <span class="Italics">Mycoplasma pneumoniae 
</span>.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mild to moderate severity caused by 
<span class="Italics">Streptococcus pyogenes</span> or <span class="Italics">Staphylococcus aureus</span> (resistant staphylococci may emerge 
during treatment).</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to <span class="Italics">Corynebacterium diphtheriae 
</span>, as an adjunct to antitoxin, to prevent establishment of carriers and to 
eradicate the organism in carriers.</p>
<p>Erythrasma: In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Corynebacterium minutissimum</span>.</p>
<p>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by <span class="Italics">Entamoeba 
histolytica</span> (oral erythromycins only). Extraenteric <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> requires 
treatment with other agents.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">Neisseria 
gonorrhoeae:</span> As an alternative drug in treatment of acute pelvic 
inflammatory disease caused by <span class="Italics">N. gonorrhoeae</span> in 
female patients with a history of sensitivity to penicillin. Patients should 
have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving erythromycin as treatment of 
<span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and a follow-up serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3 months.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> Caused by <span class="Italics">Treponema Pallidum </span>: 
Erythromycin is an alternate choice of treatment for primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in 
penicillin-allergic patients. In primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, spinal fluid examinations 
should be done before treatment and as part of follow-up after therapy.</p>
<p>Erythromycins are indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
caused by <span class="Italics">Chlamydia trachomatis:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> of 
the newborn, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of infancy, and urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy. 
When tetracyclines are contraindicated or not tolerated, erythromycin is 
indicated for the treatment of uncomplicated urethral, endocervical, or rectal 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults due to <span class="Italics">Chlamydia 
trachomatis</span>.</p>
<p>When tetracyclines are contraindicated or not tolerated, erythromycin is 
indicated for the treatment of nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</p>
<p>Legionnaires' Disease caused by <span class="Italics">Legionella 
pneumophila</span>. Although no controlled clinical efficacy studies have been 
conducted, <span class="Italics">in vitro</span> and limited preliminary clinical 
data suggest that erythromycin may be effective in treating Legionnaires' 
Disease.</p>
<a href="http://"></a><a href="http://"></a>Prophylaxis<a href="http://"></a><a href="http://"></a>Prevention of Initial Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span><p>Penicillin is considered by the American Heart Association to be 
the drug of choice in the prevention of initial attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> 
(treatment of <span class="Italics">Streptococcus pyogenes</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of 
the upper respiratory tract, e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Erythromycin is 
indicated for the treatment of penicillin-allergic patients.<span class="Sup">3</span> The therapeutic dose should be administered for 10 
days.</p>
<a href="http://"></a><a href="http://"></a>Prevention of Recurrent Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span><p>Penicillin or sulfonamides are considered by the American Heart 
Association to be the drugs of choice in the prevention of recurrent attacks of 
<span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In patients who are allergic to penicillin and sulfonamides, 
oral erythromycin is recommended by the American Heart Association in the 
long-term prophylaxis of <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> (for the prevention of 
recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>).<span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Erythromycin is contraindicated in patients with known 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine, astemizole, 
pimozide, or cisapride. (See <span class="Bold">PRECAUTIONS - Drug Interactions 
</span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">There have been reports of hepatic dysfunction, including 
increased liver enzymes, and hepatocellular and/or chloestatic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, with 
or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin 
products.</p>
<p>There have been reports suggesting that erythromycin does not reach the fetus 
in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women 
treated during pregnancy with oral erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be 
treated with an appropriate penicillin regimen.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all 
antibacterial agents, including erythromycin, and may range in severity from 
mild to life threatening. Therefore, it is important to consider this diagnosis 
in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of 
antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and 
may permit overgrowth of clostridia. Studies indicate that a toxin produced by 
<span class="Italics">Clostridium difficile</span> is a primary cause of 
"antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>".</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, 
therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> 
usually respond to discontinuation of the drug alone. In moderate to severe 
cases, consideration should be given to management with fluids and electrolytes, 
protein supplementation, and treatment with an antibacterial drug clinically 
effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in 
seriously ill patients receiving erythromycin concomitantly with lovastatin. 
Therefore, patients receiving concomitant lovastatin and erythromycin should be 
carefully monitored for creatine kinase (CK) and serum transaminase levels. (See 
package insert for lovastatin.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<p class="First">Prescribing erythromycin ethylsuccinate tablets in the absence of 
a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication 
is unlikely to provide benefit to the patient and increases the risk of the 
development of drug-resistant bacteria.</p>
<p>Since erythromycin is principally excreted by the liver, caution should be 
exercised when erythromycin is administered to patients with impaired hepatic 
function. (See <span class="Bold">CLINICAL PHARMACOLOGY</span> and <span class="Bold">WARNINGS</span> sections.)</p>
<p>There have been reports that erythromycin may aggravate the <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of 
patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>There have been reports of infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> (IHPS) 
occurring in infants following erythromycin therapy. In one cohort of 157 
newborns who were given erythromycin for <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis, seven neonates 
(5%) developed symptoms of non-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">bilious vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding and 
were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A 
possible dose-response effect was described with an absolute risk of IHPS of 
5.1% for infants who took erythromycin for 8-14 days and 10% for infants who 
took erythromycin for 15-21 days.<span class="Sup">4</span> Since erythromycin may 
be used in the treatment of conditions in infants which are associated with 
significant mortality or morbidity (such as <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> or neonatal Chlamydia 
trachomatis <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), the benefit of erythromycin therapy needs to be weighed 
against the potential risk of developing IHPS. Parents should be informed to 
contact their physician if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding occurs.</p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of 
nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should 
be discontinued and appropriate therapy instituted.</p>
<p>When indicated, incision and drainage or other surgical procedures should be 
performed in conjunction with antibiotic therapy.</p>
<a href="http://"></a><a href="http://"></a>Information for Patients<p>Patients should be counseled that antibacterial drugs including 
erythromycin ethylsuccinate tablets should only be used to treat bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When 
erythromycin ethylsuccinate tablets is prescribed to treat a bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, patients should be told that although it is common to feel better 
early in the course of therapy, the medication should be taken exactly as 
directed. Skipping doses or not completing the full course of therapy may (1) 
decrease the effectiveness of the immediate treatment and (2) increase the 
likelihood that bacteria will develop resistance and will not be treatable by 
erythromycin ethylsuccinate tablets or other antibacterial drugs in the 
future.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>Erythromycin use in patients who are receiving high doses of 
theophylline may be associated with an increase in serum theophylline levels and 
potential theophylline toxicity. In case of theophylline toxicity and/or 
elevated serum theophylline levels, the dose of theophylline should be reduced 
while the patient is receiving concomitant erythromycin therapy.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to 
result in elevated digoxin serum levels.</p>
<p>There have been reports of increased anticoagulant effects when erythromycin 
and oral anticoagulants were used concomitantly. Increased anticoagulation 
effects due to interactions of erythromycin with various oral anticoagulants may 
be more pronounced in the elderly.</p>
<p>Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the 
cytochrome p450 enzyme system (CYP3A). Coadministration of erythromycin and a 
drug primarily metabolized by CYP3A may be associated with elevations in drug 
concentrations that could increase or prolong both the therapeutic and adverse 
effects of the concomitant drug. Dosage adjustments may be considered, and when 
possible, serum concentrations of drugs primarily metabolized by CYP3A should be 
monitored closely in patients concurrently receiving erythromycin.</p>
<p>The following are examples of some clinically significant CYP3A based drug 
interactions. Interactions with other drugs metabolized by the CYP3A isoform are 
also possible. The following CYP3A based drug interactions have been observed 
with erythromycin products in post-marketing experience:</p>
<a href="http://"></a><a href="http://"></a>Ergotamine/dihydroergotamine<p>Concurrent use of erythromycin and ergotamine or 
dihydroergotamine has been associated in some patients with acute ergot toxicity 
characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>.</p>
<a href="http://"></a><a href="http://"></a>Triazolobenzodiazepines (Such as Triazolam and Alprazolam) 
and Related Benzodiazepines<p>Erythromycin has been reported to decrease the clearance of 
triazolam and midazolam, and thus, may increase the pharmacologic effect of 
these benzodiazepines.</p>
<a href="http://"></a><a href="http://"></a>HMG-CoA Reductase Inhibitors<p>Erythromycin has been reported to increase concentrations of 
HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of 
<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking these drugs 
concomitantly.</p>
<a href="http://"></a><a href="http://"></a>Sildenafil (Viagra)<p>Erythromycin has been reported to increase the systemic exposure 
(AUC) of sildenafil. Reduction of sildenafil dosage should be considered. (See 
Viagra package insert.)</p>
<a href="http://"></a><p>There have been spontaneous or published reports of CYP3A based 
interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, 
alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, 
vinblastine, and bromocriptine.</p>
<p>Concomitant administration of erythromycin with cisapride, pimozide, 
astemizole, or terfenadine is contraindicated. (See <span class="Bold">CONTRAINDICATIONS </span>.)</p>
<p>In addition, there have been reports of interactions of erythromycin with 
drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, 
and valproate.</p>
<p>Erythromycin has been reported to significantly alter the metabolism of the 
nonsedating antihistamines terfenadine and astemizole when taken concomitantly. 
Rare cases of serious cardiovascular adverse events, including 
electrocardiographic QT/QT<span class="Sub">c</span> interval prolongation, 
<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> have been 
observed. (See <span class="Bold">CONTRAINDICATIONS</span>.) In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> 
have been reported rarely with concomitant administration of terfenadine and 
erythromycin.</p>
<p>There have been post-marketing reports of drug interactions when erythromycin 
was coadministered with cisapride, resulting in QT prolongation, cardiac 
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and torsades de 
pointes most likely due to the inhibition of hepatic metabolism of cisapride by 
erythromycin. Fatalities have been reported. (See <span class="Bold">CONTRAINDICATIONS</span>.)</p>
<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions<p>Erythromycin interferes with the fluorometric determination of 
urinary catecholamines.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Long-term (2-year) oral studies conducted in rats with 
erythromycin ethylsuccinate and erythromycin base did not provide evidence of 
tumorigenicity. Mutagenicity studies have not been conducted. There was no 
apparent effect on male or female fertility in rats fed erythromycin (base) at 
levels up to 0.25% of diet.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a>Teratogenic Effects.<a href="http://"></a><a href="http://"></a>Pregnancy Category B<p>There is no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse 
effect on reproduction in female rats fed erythromycin base (up to 0.25% of 
diet) prior to and during mating, during gestation, and through weaning of two 
successive litters. There are, however, no adequate and well-controlled studies 
in pregnant women. Because animal reproduction studies are not always predictive 
of human response, this drug should be used during pregnancy only if clearly 
needed.</p>
<a href="http://"></a><a href="http://"></a>Labor and Delivery<p>The effect of erythromycin on labor and delivery is 
unknown.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Erythromycin is excreted in human milk. Caution should be 
exercised when erythromycin is administered to a nursing woman.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>See <span class="Bold">INDICATIONS AND USAGE</span> and <span class="Bold">DOSAGE AND ADMINISTRATION</span> sections.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent side effects of oral erythromycin preparations 
are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, 
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic 
dysfunction and/or abnormal liver function test results may occur. (See <span class="Bold">WARNINGS</span> section.)</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after 
antibacterial treatment. (See <span class="Bold">WARNINGS</span>.)</p>
<p>Rarely, erythromycin has been associated with the production of ventricular 
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, in 
individuals with prolonged QT intervals.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred. Skin 
reactions ranging from mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, Stevens-Johnson 
syndrome, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely.</p>
<p>There have been isolated reports of reversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurring chiefly 
in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients receiving high doses of 
erythromycin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, erythromycin should be discontinued. 
Overdosage should be handled with the prompt elimination of unabsorbed drug and 
all other appropriate measures should be instituted.</p>
<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Erythromycin ethylsuccinate tablets may be administered without 
regard to meals. To avoid unpleasant taste, the 400 mg tablets should not be 
chewed.</p>
<a href="http://"></a><a href="http://"></a>Children<p>Age, weight, and severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are important factors 
in determining the proper dosage. In mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> the usual 
dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day in 
equally divided doses every 6 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> this dosage may 
be doubled. If twice-a-day dosage is desired, one-half of the total daily dose 
may be given every 12 hours. Doses may also be given three times daily by 
administering one-third of the total daily dose every 8 hours.</p>
<p>The following dosage schedule is suggested for mild to moderate 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<a href="http://"></a><a name="iff43b9f4-3ad3-490b-8a00-535f66dc5e32"></a><table width="100%">
<col width="50%">
<col width="50%">
<thead><tr class="First Last">
<td><span class="Bold">Body Weight</span></td>
<td><span class="Bold">Total Daily Dose</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td>Under 10 lbs</td>
<td>30-50 mg/kg/day<br>15-25 mg/lb/day</td>
</tr>
<tr>
<td>10 to 15 lbs</td>
<td>200 mg</td>
</tr>
<tr>
<td>16 to 25 lbs</td>
<td>400 mg</td>
</tr>
<tr>
<td>26 to 50 lbs</td>
<td>800 mg</td>
</tr>
<tr>
<td>51 to 100 lbs</td>
<td>1200 mg</td>
</tr>
<tr class="Last">
<td>over 100 lbs</td>
<td>1600 mg</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a>Adults<p>400 mg erythromycin ethylsuccinate every 6 hours is the usual 
dose. Dosage may be increased up to 4 g per day according to the severity of the 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If twice-a-day dosage is desired, one-half of the total daily dose 
may be given every 12 hours. Doses may also be given three times daily by 
administering one-third of the total daily dose every 8 hours.</p>
<p>For adult dosage calculation, use a ratio of 400 mg of erythromycin activity 
as the ethylsuccinate to 250 mg of erythromycin activity as the stearate, base 
or estolate.</p>
<a href="http://"></a><p>In the treatment of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic 
dosage of erythromycin ethylsuccinate should be administered for at least 10 
days. In continuous prophylaxis against recurrences of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> 
in persons with a history of rheumatic heart disease, the usual dosage is 400 mg 
twice a day.</p>
<a href="http://"></a><a href="http://"></a>For Treatment of <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">Urethritis</span> Due to <span class="Italics">C. 
trachomatis</span> or <span class="Italics">U. urealyticum</span><p>800 mg three times a day for 7 days.</p>
<a href="http://"></a><a href="http://"></a>For Treatment of Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span><a href="http://"></a><a href="http://"></a>Adults<p>48 to 64 g given in divided doses over a period of 10 to 15 
days.</p>
<a href="http://"></a><a href="http://"></a>For Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span><a href="http://"></a><a href="http://"></a>Adults<p>400 mg four times daily for 10 to 14 days.</p>
<a href="http://"></a><a href="http://"></a>Children<p>30 to 50 mg/kg/day in divided doses for 10 to 14 days.</p>
<a href="http://"></a><a href="http://"></a>For Use in <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span><p>Although optimal dosage and duration have not been established, 
doses of erythromycin utilized in reported clinical studies were 40 to 50 
mg/kg/day, given in divided doses for 5 to 14 days.</p>
<a href="http://"></a><a href="http://"></a>For Treatment of Legionnaires' Disease<p>Although optimal doses have not been established, doses utilized 
in reported clinical data were those recommended above (1.6 to 4 g daily in 
divided doses.)</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Erythromycin ethylsuccinate Tablets, USP, 400 mg are supplied as 
mottled pink, oval tablets bearing the Code 74 ZE in:</p>
<p> bottles of 15 (<span class="Bold">NDC</span> 54868-0018-5)</p>
<p>bottles of 20 (<span class="Bold">NDC</span> 54868-0018-3)</p>
<p> bottles of 30 (<span class="Bold">NDC</span> 54868-0018-4)</p>
<p>bottles of 40 (<span class="Bold">NDC</span> 54868-0018-1)</p>bottles of 60 (<span class="Bold">NDC</span> 54868-0018-9)
<p>bottles of 100 (<span class="Bold">NDC</span> 54868-0018-7)</p>
<a href="http://"></a><a href="http://"></a><p> bottles of 120 (<span class="Bold">NDC</span> 54868-0018-6).</p>
<p><br></p>Recommended Storage<p>Protect tablets from exposure to light and moisture. Store below 
86°F (30°C).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCE</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards, <span class="Italics">Method for Dilution Antimicrobial Susceptibility Tests for 
Bacteria that Grow Aerobically</span>, Third Edition. Approved Standard NCCLS 
Document M7-A3, Vol. 13, No. 25. NCCLS, Villanova , PA, December 1993.</li>
<li>National Committee for Clinical Laboratory Standards, <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility 
Tests</span>, Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, 
No. 24. NCCLS, Villanova , PA, December 1993.</li>
<li>Committee on <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, and Kawasaki Disease of the 
Council on Cardiovascular Disease in the Young, the American Heart Association: 
Prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>. <span class="Italics">Circulation</span>. 
78(4):1082-1086, October 1988.</li>
<li>Honein, M.A., et. al.: Infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> after 
<span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis with erythromycin: a case review and cohort study. The 
Lancet 1999; 354(9196):2101-5.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First">Abbott Laboratories</p>
<p>North Chicago, IL 60064, U.S.A.</p>
<br><p><br></p>
<p>Relabeling and Repackaging by:<br>Physicians Total Care, Inc.<br>Tulsa, OK     74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Erythromycin ethylsuccinate Tablets, USP, 400 mg <br></p>
<p><img alt="image of 400 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d8c343b-30d9-4cdb-8f55-2a20983a71c1&amp;name=400mg%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYTHROMYCIN ETHYLSUCCINATE 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0018(NDC:0074-2589-13)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN ETHYLSUCCINATE</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN ETHYLSUCCINATE</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">74;ZE</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0018-1</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-0018-3</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-0018-4</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-0018-5</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-0018-6</td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-0018-7</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:54868-0018-9</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA061904</td>
<td class="formItem">02/27/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>34ac3461-e6e3-4b5d-9c40-895dc9ca2d73</div>
<div>Set id: 6d8c343b-30d9-4cdb-8f55-2a20983a71c1</div>
<div>Version: 1</div>
<div>Effective Time: 20100729</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
